Relapsed/Refractory Advanced Tumors
Conditions
Interventions
Observation Group:None
Sponsors
Shanghai Fengxian District Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Volunteers are required to sign the written informed consent form voluntarily, and be aged >= 18 years old when signing the informed consent form, with no gender limitation. 2.Patients with histologically, cytologically or radiologically confirmed advanced prostate cancer, lung cancer or hematological tumors, who have failed standard treatment, or have no standard treatment protocol available, or are not suitable for standard treatment, or have refused to receive standard treatment, and are currently receiving palliative treatment. 3.For patients with solid tumors, there should be at least one measurable lesion according to the RECIST 1.1 standard. That is, for non-lymph node lesions, the long diameter should be >= 10 mm based on CT or MRI cross-sectional images, or for lymph node lesions, the short diameter should be >= 15 mm; the longest axis of the measurable lesion should be >= 10 mm on CT scan (with CT scan slice thickness<= 5 mm). 4.Patients with a performance status of 0 - 3 according to the Eastern Cooperative Oncology Group (ECOG) score. 5.The expected survival period should be no less than 12 weeks.
Exclusion criteria
Exclusion criteria: 1.Any situation that may impede the subjects from completing the clinical trial process, including but not limited to severe and uncontrollable organic lesions or infections, unstable angina pectoris, congestive heart failure, etc. 2.Patients with symptomatic, uncontrollable neurological, psychiatric diseases or mental disorders. 3.Female patients who are pregnant or breastfeeding, or those with positive baseline pregnancy test results among women of childbearing age. 4.Patients who are allergic to the components of the samples, such as being allergic to seafood. 5.Those who are considered by the researchers as not suitable to participate in this study. 6.Having participated in other interventional clinical trials (including drugs, nutritional preparations, medical devices, etc.) within 4 weeks before screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression - free Survival;Overall Survival;Improvement in immune function parameter levels;Improvement in nutritional status; | — |
Countries
China
Contacts
Public ContactSun Zhenliang
Shanghai Fengxian District Central Hospital
Outcome results
None listed